Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Pegcantratinib (Primary)
  • Indications Plaque psoriasis; Pruritus
  • Focus Therapeutic Use
  • Sponsors Sienna Biopharmaceuticals
  • Most Recent Events

    • 03 Dec 2018 According to a Sienna Biopharmaceuticals media release, subjects treated with SNA-120 (0.05%) achieved statistical significance, compared to vehicle, on important pre-specified regulatory endpoints of psoriasis disease severity.
    • 03 Dec 2018 Primary endpoint (Mean change from baseline to week eight on the Itch Numeric Rating Scale (I-NRS): SNA-120 (0.05%) versus vehicle) has not been met, according to results presented in a Sienna Biopharmaceuticals media release.
    • 03 Dec 2018 Results presented in a Sienna Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top